Callitas Health Inc (CNSX:LILY), a clinical-stage company focused on weight management and female health, has been granted a patent relating to fertility treatment.
The United States Patent and Trademark Office (USPTO) has granted notice of allowance for the company’s patent application for In Vivo Sperm Selection for Treating Male Infertility.
This patent notice of allowance expands Callitas's intellectual property portfolio and furthers the patent protected formula, and uses of, the ToConceive product, allowing it to be used to treat male infertility (or sub-fertility) caused by a reduced number of normal, functional sperm in the male partner.
“Male infertility (or sub-fertility) does not receive the attention it should,” said James Thompson, the interim president and chief executive officer of Callitas.
“Statistics indicate that nearly two-thirds of all infertility challenges are linked back to the male partner, and can be heightened with a lack of lubrication from the woman.
“This patent notice of allowance helps strengthen our core intellectual property assets of the ToConceive brand and reinforces Callitas’s commitment to female health and wellness,” Thompson added.
Callitas plans to expand its intellectual property portfolio with additional divisional applications from this current grant, as well as, additional patents in the female fertility and sexual wellness space.
Shares in Callitas were up 3.1% at C$0.33.